Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shakeel Modak

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9Shakeel Modak, Hong Fen Guo, John L Humm, et al.
International Journal of Radiation Oncology, Biology, Physics|May 12, 2009
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastomaBrian H Kushner, Nai-Kong V Cheung, Christopher A Barker, et al.
Pediatric Blood & Cancer|November 2, 2007
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapyShakeel Modak, Neeta Pandit-Taskar, Brian H Kushner, et al.
Pediatric Blood & Cancer|July 31, 2021
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastomaSanam Shahid, Brian H Kushner, Shakeel Modak, et al.
International Journal of Cancer|August 1, 2022
Immunotherapy with anti-G<sub>D2</sub> monoclonal antibody in infants with high-risk neuroblastomaBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumorsShakeel Modak, Sharon Gardner, Ira J Dunkel, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2010
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastomaVictoria J Croog, Kim Kramer, Nai-Kong V Cheung, et al.
Cancers|December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk NeuroblastomaFiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2018
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?Dana L Casey, Ken L Pitter, Brian H Kushner, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Cancer Biotherapy & Radiopharmaceuticals|October 27, 2005
Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9Shakeel Modak, Hong Fen Guo, John L Humm, et al.
International Journal of Radiation Oncology, Biology, Physics|May 12, 2009
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastomaBrian H Kushner, Nai-Kong V Cheung, Christopher A Barker, et al.
Pediatric Blood & Cancer|November 2, 2007
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapyShakeel Modak, Neeta Pandit-Taskar, Brian H Kushner, et al.
Pediatric Blood & Cancer|July 31, 2021
Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastomaSanam Shahid, Brian H Kushner, Shakeel Modak, et al.
International Journal of Cancer|August 1, 2022
Immunotherapy with anti-G<sub>D2</sub> monoclonal antibody in infants with high-risk neuroblastomaBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumorsShakeel Modak, Sharon Gardner, Ira J Dunkel, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2010
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastomaVictoria J Croog, Kim Kramer, Nai-Kong V Cheung, et al.
Cancers|December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk NeuroblastomaFiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2018
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?Dana L Casey, Ken L Pitter, Brian H Kushner, et al.
Pageof 14